{"id":"ant-1207","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, ANT-1207 reduces glucose reabsorption in the kidneys, leading to decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating diabetes.","oneSentence":"ANT-1207 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:09:50.094Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02479139","phase":"PHASE2","title":"Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-06-03","conditions":"Hyperhidrosis","enrollment":145},{"nctId":"NCT01293552","phase":"PHASE2","title":"Clinical Trial To Evaluate ANT-1207 In Subjects With Acne","status":"COMPLETED","sponsor":"Anterios Inc.","startDate":"2011-01","conditions":"Acne Vulgaris","enrollment":72},{"nctId":"NCT01358695","phase":"PHASE2","title":"Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet","status":"COMPLETED","sponsor":"Anterios Inc.","startDate":"2011-05","conditions":"Lateral Canthal Lines, Crow's Feet","enrollment":111}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ANT-1207","genericName":"ANT-1207","companyName":"Anterios Inc.","companyId":"anterios-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"ANT-1207 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}